Welt Bio-Molecular Pharmaceutical, LLC (WBMP) employs a proprietary platform for the discovery and development of first-in-class directly active monoclonal antibodies (mAbs) for the treatment of cancers and autoimmune diseases. Our lead product, a mAb therapy for B-cell-derived leukemias and lymphomas, has shown high specificity to, and efficacy in eradicating malignant B-cells. We are working towards completing pre-clinical requirements for this product, while expanding our mAb pipeline by discovering and targeting novel, biologically active epitopes in these and other cancers.
Our Team
SYDNEY WELT, MD
Principal and CEO
Dr. S. Welt has over 40 years of experience in immunology and antibody development from benchtop, experimental models, radio-immunotherapy and immune effector functions, to clinical development through Phase I/II studies. He is board certified in internal medicine and oncology.
DAVID KOSTYAL, PhD
Partner and CSO
Dr. Kostyal is a global expert in allergens and antibody reactivity and established the first FDA approved allergen test and protein bank used as the national testing standard. He has conducted immune and molecular assays for WBMP, and was instrumental in developing the novel immunization strategies that yielded WBMP’s lead mAb products.
RACHEL WELT, PhD
Partner and Chief Laboratory Investigator
Dr. R. Welt has over 15 years of research experience across diverse fields of biological sciences including oncology, immunology, genomics, evolutionary biology, and computational analyses. She currently directs WBMP’s research programs to further the development of our lead product, and to expand our platform through the discovery of novel therapeutic targets.
VIRGINIA RAYMOND
Regulatory Strategist
Ms. Raymond’s 30-year career in clinical research, which began at Sloan Kettering, includes 20 years at Pfizer where she served as Global Director and was involved in several high-profile portfolios. Ms. Raymond now specializes in assisting biotech companies in the immunology space with their regulatory compliance and clinical trial needs.